TherapeuticsMD (TXMD) Finished Goods (2012 - 2022)

TherapeuticsMD (TXMD) has reported Finished Goods for 11 consecutive years, with $4.5 million the latest figure, recorded in Q3 2022.

• For the quarter ending Q3 2022, Finished Goods rose 42.36% year-over-year to $4.5 million; the trailing twelve-month figure through Sep 2022 stood at $4.5 million (up 42.36% YoY), and the FY2021 full-year result was $2.9 million, down 12.3% from the prior year.
• Finished Goods advanced to $4.5 million in Q3 2022 per TXMD's latest filing, from $4.0 million in the prior quarter.
• Across five years, Finished Goods topped out at $5.0 million in Q3 2019 and bottomed at $1.6 million in Q1 2018.
• Historically, Finished Goods has averaged $3.4 million across 5 years, with a median of $3.3 million in 2019.
• The sharpest annual moves came in 2019 and 2021: Finished Goods surged 122.24% in 2019, then sank 41.45% in 2021.
• Over 5 years, Finished Goods stood at $2.9 million in 2018, then soared by 71.09% to $5.0 million in 2019, then slumped by 32.69% to $3.4 million in 2020, then decreased by 12.3% to $2.9 million in 2021, then jumped by 54.42% to $4.5 million in 2022.
• According to Business Quant data, Finished Goods over the past three periods registered $4.5 million, $4.0 million, and $3.3 million for Q3 2022, Q2 2022, and Q1 2022 respectively.